Picture of Fusion Antibodies logo

FAB — Fusion Antibodies Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-14.08%
3m-18.97%
6m-59.11%
1yr-65.11%
Volume Change (%)
10d/3m+2.51%
Price vs... (%)
52w High-69.18%
50d MA-23.47%
200d MA-50.86%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-31.12%
Return on Equity-51.86%
Operating Margin-28.4%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202231st Mar 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Fusion Antibodies EPS forecast chart

Profile Summary

Fusion Antibodies plc is a United Kingdom contract research organization (CRO) located in Northern Ireland. The Company offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.

Directors

Last Annual
March 31st, 2021
Last Interim
September 30th, 2021
Incorporated
November 29th, 2000
Public Since
December 18th, 2017
No. of Employees
54
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
26,014,946

FAB Share Price Performance

Latest News for FAB

Upcoming Events for FAB

Full Year 2022 Fusion Antibodies PLC Earnings Release

Fusion Antibodies PLC Annual Shareholders Meeting

Half Year 2023 Fusion Antibodies PLC Earnings Release

Similar to FAB

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of 4d Pharma logo

4d Pharma

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email